Drug Profile
Anthrax vaccine - Harvard University/Soligenix
Alternative Names: DNI-rPA; SGX-204; VeloThraxLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Harvard University
- Developer Soligenix
- Class Anthrax vaccines
- Mechanism of Action Immunostimulants; Toll-like receptor 4 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Anthrax
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Anthrax in USA (Parenteral)
- 19 Aug 2014 Anthrax vaccine - Harvard University/Soligenix is available for licensing in World as of 19 Aug 2014. www.soligenix.com
- 07 Aug 2014 Preclinical development is ongoing in USA